MedPath

Bold Therapeutics, Inc.

Bold Therapeutics, Inc. logo
🇨🇦Canada
Ownership
Holding
Established
2018-01-01
Employees
11
Market Cap
-
Website
http://www.bold-therapeutics.com

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Phase 1
Recruiting
Conditions
Colorectal Cancer
Pancreatic Cancer
Cholangiocarcinoma
Gastric Cancers
Interventions
Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)
Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)
First Posted Date
2020-06-09
Last Posted Date
2025-02-07
Lead Sponsor
Bold Therapeutics, Inc.
Target Recruit Count
220
Registration Number
NCT04421820
Locations
🇺🇸

University of California, Los Angeles, Santa Monica, California, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇨🇦

Cross Cancer Institue, Edmonton, Alberta, Canada

and more 11 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.